Jordan - English - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

شركة مستودع أدوية أوتار - awtar pharmaceutical co - entacapone 200 mg, levodopa 200 mg, carbidopa 50 mg - 200 mg, 200 mg, 50 mg

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

eg sa-nv - carbidopa monohydrate 54 mg - eq. carbidopa 50 mg; levodopa 200 mg; entacapone 200 mg - film-coated tablet - 200 mg - 50 mg - 200 mg - levodopa 200 mg; carbidopa monohydrate 54 mg; entacapone 200 mg - levodopa, decarboxylase inhibitor and comt inhibitor

New Zealand - English - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - amisulpride 200mg;  ;  ; amisulpride 200mg - tablet - 200 mg - active: amisulpride 200mg     excipient: hydrated silica lactose monohydrate magnesium stearate methylcellulose potato starch active: amisulpride 200mg excipient: hypromellose lactose monohydrate magnesium stearate microcrystalline cellulose sodium starch glycolate - amisulpride is indicated for the treatment of acute and chronic schizophrenic disorders, in which positive symptoms (such as delusions, hallucinations, thought disorders) and/or negative symptoms (such as blunted affect, emotional and social withdrawal) are prominent, including patients characterised by predominant negative symptoms.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - carbidopa monohydrate, quantity: 54.1 mg (equivalent: carbidopa, qty 50 mg); levodopa, quantity: 200 mg; entacapone, quantity: 200 mg - tablet, film coated - excipient ingredients: mannitol; titanium dioxide; sucrose; magnesium stearate; croscarmellose sodium; glycerol; povidone; iron oxide red; maize starch; hypromellose; polysorbate 80 - l.c.e. sandoz 200/50/200 is indicated for the management of patients with parkinson's disease who are experiencing motor fluctuations.

New Zealand - English - Medsafe (Medicines Safety Authority)

orion pharma (nz) limited - carbidopa monohydrate 54.1mg equivalent to 50 mg carbidopa; entacapone 200mg; levodopa 200mg - film coated tablet - 200mg/50mg/200mg - active: carbidopa monohydrate 54.1mg equivalent to 50 mg carbidopa entacapone 200mg levodopa 200mg excipient: croscarmellose sodium ethanol glycerol hypromellose iron oxide red magnesium stearate   maize starch mannitol polysorbate 80 povidone purified water   sucrose titanium dioxide - latest regulatory activity

Australia - English - Department of Health (Therapeutic Goods Administration)

besins healthcare australia pty ltd - progesterone, quantity: 200 mg - capsule, soft - excipient ingredients: glycerol; lecithin; titanium dioxide; gelatin; purified water; sunflower oil - prometrium 100 mg and 200 mg, soft capsules are indicated for:,treatment of menstrual irregularities,- in women with menstrual abnormalities or secondary amenorrhoea due to normogonadotrophic amenorrhoea (see dosage and administration),hormone replacement therapy,- hormone replacement therapy ? adjunctive use with an oestrogen in postmenopausal women with an intact uterus

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - amisulpride, quantity: 200 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; hypromellose; microcrystalline cellulose; sodium starch glycollate type a; magnesium stearate - amisulpride is indicated for the treatment of acute and chronic schizophrenic disorders, in which positive symptoms (such as delusions, hallucinations, thought disorders) and/or negative symptoms (such as blunted affect, emotional and social withdrawal) are prominent, including patients characterised by predominant negative symptoms.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - clozapine, quantity: 200 mg - tablet - excipient ingredients: lactose monohydrate; sodium starch glycollate; magnesium stearate; povidone; microcrystalline cellulose - treatment with clopine is indicated only in people with treatment-resistant schizophrenia, ie. people with schizophrenia who are non-responsive to, or intolerant of other antipsychotic drugs. non-responsiveness is defined as a lack of satisfactory clinical improvement despite the use of adequate doses of at least two classes of marketed antipsychotic drugs prescribed for reasonable durations. intolerance is defined as the impossibility to achieve adequate benefit with other antipsychotic drugs because of severe and untreatable neurological adverse reactions (extrapyramidal side effects or tardive dyskinesia).

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - clozapine, quantity: 200 mg - tablet - excipient ingredients: microcrystalline cellulose; magnesium stearate; povidone; lactose monohydrate; sodium starch glycollate - treatment with clopine is indicated only in people with treatment-resistant schizophrenia, ie. people with schizophrenia who are non-responsive to, or intolerant of other antipsychotic drugs. non-responsiveness is defined as a lack of satisfactory clinical improvement despite the use of adequate doses of at least two classes of marketed antipsychotic drugs prescribed for reasonable durations. intolerance is defined as the impossibility to achieve adequate benefit with other antipsychotic drugs because of severe and untreatable neurological adverse reactions (extrapyramidal side effects or tardive dyskinesia).

Australia - English - Department of Health (Therapeutic Goods Administration)

gilead sciences pty ltd - emtricitabine, quantity: 200 mg; tenofovir alafenamide fumarate, quantity: 11.2 mg (equivalent: tenofovir alafenamide, qty 10 mg) - tablet, film coated - excipient ingredients: croscarmellose sodium; magnesium stearate; microcrystalline cellulose; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3350; iron oxide black - treatment of hiv-1 infection: descovy is indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection in adults and paediatric patients weighing at least 25kg. the patients must not have a history of treatment failure or known mutations associated with resistance to the individual components of descovy (see section 5.1 pharmacodynamic properties).,hiv-1 pre-exposure prophylaxis: descovy is indicated for pre-exposure prophylaxis (prep) to reduce the risk of sexually acquired hiv-1 in at-risk adults and adolescents weighing at least 35 kg, excluding individuals at risk from receptive vaginal sex.